---
title: "Study of Combination Therapy With Dimebon and Donepezil (Aricept) in Patients With Alzheimer's Disease"
nct_id: NCT00704782
overall_status: TERMINATED
phase: PHASE2
sponsor: Medivation, Inc.
study_type: INTERVENTIONAL
primary_condition: "Alzheimer's Disease"
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT00704782.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT00704782"
ct_last_update_post_date: 2015-12-10
last_seen_at: "2026-05-12T06:10:51.013Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Study of Combination Therapy With Dimebon and Donepezil (Aricept) in Patients With Alzheimer's Disease

**Official Title:** An Open-Label Extension Study of Combination Therapy With Dimebon and Donepezil in Patients With Alzheimer's Disease

**NCT ID:** [NCT00704782](https://clinicaltrials.gov/study/NCT00704782)

## Key Facts

- **Status:** TERMINATED
- **Why Stopped:** The study was halted after a Phase 3 study of dimebon failed to show efficacy.
- **Phase:** PHASE2
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 50
- **Lead Sponsor:** Medivation, Inc.
- **Conditions:** Alzheimer's Disease
- **Start Date:** 2008-04
- **Completion Date:** 2010-08
- **CT.gov Last Update:** 2015-12-10

## Brief Summary

The purpose of this study is to assess the safety and efficacy of Dimebon in combination with donepezil (Aricept) in the treatment of Alzheimer's disease.

## Eligibility

- **Minimum age:** 50 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Alzheimer's disease
* On donepezil (Aricept)
* Caregiver who cares for the patient at least 5 days per week

Exclusion Criteria:

* Unstable medical illnesses or significant hepatic or renal disease
* Other primary psychiatric or neurological disorders
```

## Arms

- **Dimebon** (EXPERIMENTAL) — 20 mg by mouth 3 times a day

## Interventions

- **dimebon** (DRUG)

## Primary Outcomes

- **To assess the safety of Dimebon in combination with donepezil (Aricept)** _(time frame: week 6, 9, 12, 26 and every 13 weeks thereafter until study discontinuation)_

## Locations (4)

- Xenoscience, Inc., Phoenix, Arizona, United States
- Banner Alzheimer's Institute, Phoenix, Arizona, United States
- Barrow Neurological Institute, Phoenix, Arizona, United States
- Sun Health Research Institute, Sun City, Arizona, United States

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.whyStopped` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.xenoscience, inc.|phoenix|arizona|united states` — added _(2026-05-12)_
- `locations.banner alzheimer's institute|phoenix|arizona|united states` — added _(2026-05-12)_
- `locations.barrow neurological institute|phoenix|arizona|united states` — added _(2026-05-12)_
- `locations.sun health research institute|sun city|arizona|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT00704782.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT00704782*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*